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Abstract. To date, little is known about how neurodegeneration and neuroinflammation propagate in Huntington’s disease
(HD). Unfortunately, no treatment is available to cure or reverse the progressive decline of function caused by the disease, thus
considering HD a fatal disease. Mutation gene carriers typically remain asymptomatic for many years although alterations in the
basal ganglia and cortex occur early on in mutant HD gene–carriers. Positron Emission Tomography (PET) is a functional imaging
technique of nuclear medicine which enables in vivo visualization of numerous biological molecules expressed in several human
tissues. Brain PET is most powerful to study in vivo neuronal and glial cells function as well as cerebral blood flow in a plethora
of neurodegenerative disorders including Parkinson’s disease, Alzheimer’s and HD. In absence of HD–specific biomarkers for
monitoring disease progression, previous PET studies in HD were merely focused on the study of dopaminergic terminals,
cerebral blood flow and glucose metabolism in manifest and premanifest HD–gene carriers. More recently, research interest has
been exploring novel PET targets in HD including the state of phosphodiesterse expression and the role of activated microglia.
Hence, a better understanding of the HD pathogenesis mechanisms may lead to the development of targeted therapies. PET
imaging follow–up studies with novel selective PET radiotracers such as 11C-IMA–107 and 11C-PBR28 may provide insight on
disease progression and identify prognostic biomarkers, elucidate the underlying HD pathology and assess novel pharmaceutical
agents and over time.
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HUNTINGTON’S DISEASE – AN
OVERVIEW
Huntington’s disease (HD) is an autosomal progres-
sive neurodegenerative disease which is characterized
by an expanded CAG repeat in the Huntingtin
(HTT) gene on chromosome 4. HD manifests with
behavioural changes and cognitive impairment and a
movement disorder which is most commonly chorea.
The expansion of mutant HTT eventually leads to
selective degeneration in the striatal medium spiny
neurons which receive dopaminergic projections from
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the substantia nigra and glutamatergic ones from the
cortex. Post–mortem pathology studies in HD patients
have shown marked atrophies in the caudate and puta-
men nuclei, enlargement of the lateral ventricles as
well as atrophies to the cortex, thalamus, and substantia
nigra to some extent.
HD is typically diagnosed in young adults at the age
of 40 and to date no treatment is available to reverse the
progressive decline of function caused by the disease,
thus considering HD a fatal disease.
Several studies have investigated the role of a wide
range of pharmaceutical agents in managing HD symp-
toms, including dopamine depleting agents, dopamine
antagonists, benzodiazepines, glutamate antagonists,
acetylcholinesterase inhibitors, dopamine agonists,
anticonvulsants, and cannabinoids. Pallidal and sub-
thalamic nucleus deep brain stimulation as well as
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restorative therapy with allogeneic fetal tissue have
been tried treating HD individuals, however with
inconclusive results.
Still, the exact role of mutant HTT in provoking
functional decline in HD remains unknown. Little
is known about the mechanisms that underlie the
disease’s progression and propagation and in addi-
tion, there is no available biomarker to monitor HD
progression and assess experimental treatments. In
this article, we have reviewed the findings from key
Positron Emission Tomography (PET) studies in man-
ifest and premanifest HD gene–carriers summarising
their results and identifying new areas for further
research.
POSITRON EMISSION TOMOGRAPHY IN
NEUROIMAGING
PET is a functional imaging technique of nuclear
medicine with wide applications in neurology. PET
has been widely used in neuroscience research over
the past years to investigate in vivo the pathophys-
iology of several neurological conditions including
Parkinson’s, Alzheimer’s and HD. Brain PET enables
three–dimensional visualisation of biological com-
pounds available in the human brain. PET imaging
requires a PET radioligand, which is a metabolically
active compound labelled with a radioactive isotope
and a PET–CT scanner, which is a tomography scan-
ner sensitive to detect radioactivity. PET–CT scans are
carried out on an outpatient basis. Each PET ligand
has unique pharmacokinetics and characteristics and
therefore unique applications in clinical imaging stud-
ies. A PET radioligand in brain PET is synthesised to
cross the blood brain barrier and have high affinity to
a specific biological compound. The PET radioligand
is injected in the circulation of the examinee minutes
after its production, while -rays are emitted from the
decay of the radioisotope for a certain amount of time;
eg. 11C has a half–life of approximately 20 minutes, 18F
of 110 minutes, and 15O of only two minutes. Acquired
PET data are transformed to a PET workstation, where
they are reconstructed combined with CT and struc-
tural MRI data in order to quantify global and regional
distribution of the PET radioligand.
Brain PET imaging technology and radioligand syn-
thesis have shown great progress over the past decades.
Improvements in computer–based methodology have
enhanced image resolution and quantification of PET
data, while novel radioligands are more selective to the
studied disease pathology. Continued research in mul-
timodal imaging including PET–CT and PET–MR will
improve our understanding of neurodegeneration and
neuroinflammation, validate in vivo diagnostics, and
may provide biomarkers to monitor disease–modifying
therapies. Hence, the above advances will improve the
use of PET in HD as a research and clinical tool to
assess the integrity of neurotransmission, explore the
mechanisms of underlying HD pathology and monitor
disease progression.
PET TARGETS IN HD
Dopaminergic terminals
Dopaminergic neurons physiologically abound in
the basal ganglia. Both presynaptic and postsynap-
tic terminals can be targeted through PET to assess
dopaminergic function and thus reflect the integrity of
the basal ganglia dysfunction in HD.
From a postsynaptic terminal approach, PET radi-
oligands including 11C-raclopride and 11C-SCH23390
are specific to visualize the distribution of D2, D3 and
D1, D2 dopamine receptors respectively. PET studies
in humans have shown a decline of striatal postsynaptic
D1, D2 and D3 receptors availability in manifest and
premanifest HD individuals. Turjanski and colleagues
were first to show that HD patients had reduced D1 and
D2 binding in caudate and putamen more than 30% of
the normal range [1]. In addition to manifest HD, pre-
manifest mutation gene–carriers have shown a decline
in 11C-raclopride binding in the caudate and putamen
compared to the normal range [2–8].
The 11C-raclopride and 11C-SCH23390 binding
reductions in the striatum have been shown to nega-
tively correlate with disease duration in HD individuals
[9]. In fact, dopaminergic degeneration has been shown
to occur early on during the progression of the disease
also in premanifest cases. PET follow–up studies have
shown that 11C-raclopride binding reductions occur
progressively in HD [3, 5, 8, 10] as well as in the
premanifest HD [11]. The decreases in 11C-raclopride
bindings in caudate and putamen have been found to
exceed the changes caused by atrophy, as measured by
volumetric MR imaging [11].
The rate of decline in 11C-raclopride binding has
been shown to negatively correlate with disease dura-
tion [5] and that it may follow a linear [6], a non–linear
[10] or biphasic [11] progression. Annual losses of
11C-raclopride binding at premanifest HD have been
found greater than in patients at risk of developing
HD [10]. In addition, lower 11C-raclopride bind-
ing in the putamen of premanifest HD gene–carriers
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have been shown to correlate with the probability to
phenoconvert; however, not with the rate of decline in
11C-raclopride bindings [7].
The dopamine transporter (DAT) is a membrane–
spanning protein highly expressed in presynaptic
dopaminergic terminals. The DAT is responsible for
the reuptake of dopamine from the synapse back
into the cytosol. PET imaging with 11C--CIT, which
specifically binds to the DAT, has shown 50% reduc-
tions of DAT availability in the striatum of HD
individuals relative to normal controls [9]. It has
been therefore proposed that reduced DAT expression
reflects either loss of presynaptic dopaminergic termi-
nals or poor auto–regulatory feedback mechanisms.
Vesicular monoamine transporter–type 2 (VMAT2)
is a protein responsible for transporting monoamines
into synaptic vesicles. A PET study with 11C-
dihydrotetrabenazine (11C-DTBZ), which binds selec-
tively to VMAT2, showed reduced striatal binding of
11C-DTBZ in all HD patients compared to normal
range [12]. 11C-DTBZ binding reductions in the stria-
tum were more pronounced in the subgroup of patients
with the akinetic–rigid phenotype compared to the
choreiform one.
D1 binding reductions have been measured also
in the cortex and thalamus of HD patients and were
found to correlate with volume measurements of tha-
lamus and temporal cortex as well as with low scores
of selected cognitive tasks [7, 13]. Losses of 11C-
raclopride binding have been measured in temporal
and frontal cortex as well as the amygdala in preman-
ifest HD [5]. Thalamic involvement is demonstrated
in premanifest and manifest HD also for D2 receptors
[14].
Taken together, the findings of the above studies sug-
gest that the dopaminergic terminals in the striatum
and cortex get in a compromised state regardless of
the actual atrophies noted in the basal ganglia as HD
progresses. It is also proposed that the rate of HD pro-
gression varies among individuals and that it may be a
weak index to predict the onset of HD symptoms.
Cerebral blood ﬂow and glucose metabolism
PET with 18F–fludeoxyglucose (FDG) has been
widely used to target the glucose metabolism and cere-
bral blood flow. In HD, PET studies with 18F-FDG and
H215O [15] have shown an annual decrease rate across
premanifest and HD individuals compared to normal
controls, suggestive that hypometabolism occurs in
HD and actually precedes the clinical manifestation
[3, 11, 16, 17]. The areas which have been studied to
be most affected are the striatum, frontal and temporal
cortex.
An interesting study employed 18F-FDG PET in HD
patients who were divided clinically in two groups
for fast and slow progression rate. 18F-FDG follow-up
PET showed lower glucose metabolism in frontotem-
poral and parietal cortex in the faster group compared
to the slower one [18].
Striatal reductions of 18F-FDG have been found
to decline in premanifest HD over time similarly to
the annual decline observed in 11C-raclopride binding
[3]. Nonetheless, in premanifest HD gene–carriers, the
decreases in 18F-FDG binding have been less great
compared to the ones observed through imaging of
dopaminergic terminals in HD [3, 11]. Another 18F-
FDG PET study looked into the decline of metabolic
rate in premanifest HD, and suggested that greater
losses of 18F-FDG in caudate may contribute to a
CAG–age approach for predicting disease’s onset [17].
Network analysis of 18F-FDG PET data has shown a
significant HD–specific spatial characteristics covari-
ance pattern characterized by progressive metabolic
decline in cortical and striato–thalamic activity net-
work [6, 8].
Hence, the above studies may suggest that glucose
hypometabolism is progressive in both premanifest
and manifest cases of HD gene–carriers. However,
results from PET 18F-FDG studies are inconclusive
as to whether 18F-FDG PET can be used to predict the
time HD gene–carriers phenoconvert.
PET imaging of cerebral blood flow has been
employed also to study the mechanisms underlying
abnormal cognition in premanifest HD. SPM analy-
sis of H215O PET data showed increased thalamic and
cortical activation in premanifest HD gene–carriers
compared to controls, during the performance of
learning and execution motor tasks. Premanifest HD
gene–carriers showed impaired learning performance
but normal execution of motor tasks, suggesting that
enhanced activation of thalamocortical pathways is
perhaps compensating the striatal degeneration in pre-
manifest HD [19].
In comparison to monoamines PET radioligands, it
can be therefore proposed that glucose metabolism is
indeed interesting in HD, however, may serve as a
less robust index for assessing HD dysfunction and
progression.
Cannabinoid system
The cannabinoid system has focused great research
interest in several neurodegenerative disorders. A PET
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study with 18F-MK9470, which specifically binds to
cannabinoid receptors–type 1 (CB1), looked into a
cohort of 20 symptomatic HD patients and found
a widespread reduction in the CB1 receptors avail-
ability relative to controls in the cortex, brainstem
and cerebellum. However, no correlations were found
between 18F-MK9470 bindings and clinical unified
Huntington’s disease rating scale (UHDRS) motor
scores, disease duration, and the CAG length [20].
Opioid system
PET imaging with 11C–diprenorphine, which is
a non–selective partial agonist for the delta, kappa,
and mu opioid receptors, has shown reduced binding
in the caudate and putamen in manifest HD patients
relative to normal controls [21]. The above study is
interesting also from a methodology point of view;
the authors analysed the PET data using an ROI
approach of static and dynamic data, spectral voxel
approach of dynamic data and a group analysis of
voxel-based parametric images using SPM. Among
the different approaches, it was the results from
dynamic time–activity curves which showed larger
differences and greater significance.
PD10
Phosphodiesterase 10 (PD10) is highly expressed
by the medium spiny neurons in the striatum and is
believed to play a role in the dopaminergic and gluta-
marergic neurotransmission. In addition, in the animal
model of HD, mutant HTT has been suggested to pos-
sibly downgrade the expression of PD10. PET imaging
with 18F-MNI-659, which specifically binds to PD10,
has showed reduced 18F-MNI-659 binding in the basal
ganglia of HD individuals relative to controls [22].
Very recently, a PET imaging study with 11C-IMA–107
which is a highly–selective PD10 radioligand, looked
into a cohort of premanifest HD individuals who had
further probability. The authors showed reduced 11C-
IMA–107 binding in the caudate, putamen and globus
pallidus and increased binding in motor thalamic nuclei
compared to controls, suggesting that PD10 alterations
occur several years before the predicted development
of symptomatic disease [23].
Further studies including larger numbers of partic-
ipants and follow–up scans may suggest that PD10
PET imaging is a promising biomarker for monitor-
ing HD progression as well as assess PD10–orientated
treatments.
Microglia in HD
Recent studies on the role of microglia in HD have
suggested that activated microglia may aggravate the
pathology in HD and contribute to the propagation of
the disease.
Microglia consist less than 10% of the cells in
the human brain [24]. In physiological conditions,
microglia remains in a resting state representing the
main phagocytic cells of the human brain. Traumatic
injury, ischaemia, central nervous system inflam-
mation, and neurodegeneration lead microglia to
proliferate, change morphology, gene expression and
function which is defined as activated microglia [25].
However, activated microglia, besides being phago-
cytic cells, secrete several hazardous neurotoxins such
as free radicals, nitric oxide, proteinases, and inter-
leukines. Activated microglia may therefore cause
neuronal damage and aggravate underlying pathol-
ogy. In fact, mutant HTT expression in microglia has
been linked to an increase in the expression of several
inflammatory response genes [26].
In particular, activated microglia have been found
in HD individuals in the caudate and putamen nuclei,
the globus pallidus and cortical areas in all grades of
pathology compared to controls [27]. In addition, the
dysregulating role of activated microglia in HD has
been supported by studies in the animal model of HD
[28, 29].
Currently, PET imaging of microglia has devel-
oped PET radioligands which specifically bind to
the translocator protein (TSPO). TSPO is an 18 kDa
protein mainly found in the outer mitochondrial mem-
brane, which translocates the cholesterol. TSPO is
highly expressed in activated microglia compared to
physiological microglia state. Quantification of TSPO
binding is therefore believed to reflect the state of acti-
vated microglia.
An interesting PET study with the TSPO radioli-
gand 11C-(R)-PK11195 showed increased 11C-(R)-
PK11195 binding in the whole striatum and globus
pallidum which correlated with striatal decreases in
11C-raclopride binding. In addition, lower 11C-(R)-
PK11195 binding correlated with higher UHDRS
scores [30]. The above results were explored further
with 11C-(R)-PK11195 PET in a group of premani-
fest HD gene–carriers. The striatal 11C-(R)-PK11195
bindings of gene–carriers inversely correlated with
11C-raclopride bindings. Moreover, higher striatal
11C-(R)-PK11195 bindings correlated with higher
probability [31] of HD diagnosis within five years
[32]. 11C-(R)-PK11195 increased bindings in the post-
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Table 1
Summary table of key PET studies in Huntington disease (HD) studies
Short name of PET
radioligand
PET radioligand target Relevance to HD pathology Utility for tracking disease
progression in HD clinical
trials.
References
Dopaminergic terminals
11C-raclopride
11C-SCH23390
11C--CIT
11C-DTBZ
D2 and D3 dopamine
receptors
D1 and D2 dopamine
receptors
Dopamine transporter
Vesicular monoamine
transporter–type 2
Striatal medium spiny neurons
receive dopaminergic projections
from substantia nigra. Post mortem
studies suggest degeneration of
striatal medium spiny neurons in
HD individuals.
Dopaminergic PET radioligands
including 11C--CIT and
11C-raclopride have been
useful to monitor progression
in Parkinson’s disease and
could be used to monitor HD
progression. Nonetheless, in
HD, past clinical trials with
dopaminergic medicines had
inconclusive results for
managing HD symptoms.
1–11, 13-14, 32, 34,
42, 44, 45
1, 2, 9, 10, 13, 42, 44
9, 13
12
Cerebral blood ﬂow and
glucose metabolism
18F–FDG
H215O
Glucose metabolism
Cerebral blood flow
Non–specific to HD pathology. Past PET studies in cerebral
blood flow and glucose
metabolism have been
inconclusive as to whether PET
imaging can detect time of
clinical manifestation and
monitor HD progression.
3, 6–8, 11, 16–18,
41–44, 46
15, 19
Cannabinoid system
18F-MK9470 cannabinoid
receptors–type 1 (CB1)
Post mortem studies suggest loss of
CB1 protein in the basal ganglia of
HD individuals.
Lack of evidence that modulation
of the cannabinoid system can
improve HD patients clinically
and that 18F-MK9470 PET
imaging can be used to monitor
HD progression.
20
Opioid system
11C–diprenorphine δ, κ, and  opioid
receptors
Post mortem studies in HD have
shown reduced striatal, nigral and
pallidal engkefalin and dynorphin
expression and loss of opioid
receptors.
Lack of evidence that
PD10A–orientated treatments
can improve HD patients
clinically.
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Table 1
(Continued)
Short name of PET
radioligand
PET radioligand target Relevance to HD pathology Utility for tracking disease
progression in HD clinical
trials.
References
11C–diprenorphine has favorable
kinetics but is a less selective
PET radioligand for imaging
the opioid system.
Phosphodiesterase 10 (PD10)
18F-MNI-659
11C-IMA–107
PD10A
PD10A
PD10A is highly expressed in striatal
medium spiny neurons. Post
mortem studies suggest
degeneration of striatal medium
spiny neurons in HD individuals.
Animal studies suggest a direct
effect of mutant Huntingtin protein
on PD10A expression.
Lack of evidence that
PD10A–orientated treatments
can improve HD patients
clinically.
11C-IMA–107 has favorable
kinetics and could be a
potential PET ligand to assess
the efficacy of
PD10A–orientated drugs.
22
23
Neuroinﬂammation –
Microglia activation
11C-DAA1106
11C-(R)-PK11195
3H-PK11195
11C-PBR28
Translocator protein
(TSPO)– microglia
TSPO – microglia
TSPO – microglia
Preclinical studies suggest that TSPO
is highly expressed in activated
microglia. Activated microglia has
been shown that it may aggravate
neurodegeneration and contribute
to the propagation of several
neurodegenerative diseases
including HD.
Lack of evidence that microglia
modulators can improve HD
patients clinically.
The rs6971 polymorphism of the
TSPO gene has explained the
different binding affinities of
TSPO PET radioligands in
normal controls. Among TSPO
PET radioligands, 11C-PBR28
has favorable kinetics and can
differentiate between high,
mixed and low affinity TSPO
binders and may be useful to
monitor HD progression.
39
14, 30, 32–34, 37
35–40
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central gyrus have been also found to strongly correlate
with peripheral cytokine expression [33]. In addition,
substantial microglia activation in regions related to
cognition have been suggested to predict disease onset
[34].
The above studies suggest that neuroinflammation
alterations in microglia, as reflected by TSPO PET,
occur in HD starting early on until the clinical manifes-
tation. From a neuroinflammation point of view, PET
imaging with TSPO radioligands can be therefore most
powerful to assess the role of activated microglia in HD
and assess treatments which target the modulation of
neuroinflammation.
DISCUSSION AND CONCLUSION
PET imaging can provide robust evidence for
assessing the efficacy of novel therapeutics in HD,
notwithstanding that some limitations apply.
PET imaging of dopaminergic terminals seems to
stand as a significant index of visualising neural dys-
function in the striatum, which is among the mostly
affected areas in the HD brain. A reasonable number
of studies have used dopaminergic PET imaging to
correlate their findings to clinical data relative to other
PET radioligands including 18F-FDG and TSPO ones.
Nonetheless, imaging of dopaminergic terminals do
not represent HD–specific pathology. In addition, past
clinical trials in humans with dopaminergic medicines
have had inconclusive results.
Similarly, PET imaging of glucose metabolism
may have widespread applications; however, does not
suffice to represent HD fully. The imaging of cannabi-
noid system is indeed interesting, however, there is a
lack of evidence that modulation of the cannabinoid
system can improve HD patients clinically. Striatal
11C-diprenorphine decreases observed in HD were less
great compared to the ones in dopaminergic PET imag-
ing studies. It could be therefore suggested that the
opioid receptors are relatively preserved in the striatum
through the course of the disease.
Besides the above approaches, PD10 PET studies
may provide a better understanding of the role of
mutant HTT. Hence, PD10–orientated treatments may
show significant results in managing HD symptoms
and in this view, PD10 PET can be a promising radi-
oligand for future PET studies.
From a neuroinflammation point of view, previous
TSPO radioligands including the 11C-(R)-PK11195
have been limited in research imaging studies by sec-
ond generation TSPO PET radioligands including the
11C-PBR28 which has favorable kinetics and greater
signal-to-noise ratio than 11C-(R)-PK11195 [35–38].
In humans, the 11C-PBR28 binding to TSPO has
different affinities in the general population, which
is shared among all tested second generation TSPO
radioligands including 11C-DAA1106. Owen and col-
leagues [39], demonstrated that the different affinity is
caused by the rs6971 polymorphism on the TSPO gene
resulting in three patterns of TSPO binding [40]. Sub-
jects without the polymorphism have high affinity for
11C-PBR28, homozygotes have low affinity binding,
while heterozygotes express mixed affinity binding.
Low affinity binders are easily identified by PET due
to negligible 11C-PBR28 binding in vivo. In this view,
current TSPO PET radioligands are quite promising for
visualising the state of microglia activation. TSPO is
therefore not meant to be a diagnostic target for imag-
ing in HD, but a potential biomarker for imaging HD
progression.
PET imaging can be used to monitor and assess
results from restorative therapy trials [41–46] by tar-
geting function of dopaminergic terminals and cortical
metabolic rates. Fetal transplantation trials showed sta-
bility of grafted tissue post–transplantation. However,
results from the above studies have been inconclusive
for restoring and maintaining striatal function in HD
individuals. PET studies with larger numbers of partici-
pants and multi–modal imaging including MR imaging
may provide greater robustness to future restorative
studies.
Notwithstanding, the exact mechanisms underlying
glutamatergic dysfunction of medium spiny neurons
in HD, to our knowledge, glutamatergic neurotrans-
mission has not been studied through PET in HD
individuals. In that sense, in vivo imaging of glu-
tamatergic function may improve significantly our
understanding of HD pathophysiology.
Nonetheless, design of PET radioligands for imag-
ing glutamatergic neurotransmission is challenging.
Type 1 of the metabotropic glutamate receptors’
(mGlu1) availability has been proposed to decrease
in the rodent model of HD [47] but not that of type
5 (mGlu5). Several agents have been designed as
PET radioligands for visualising mGlu1 distribution;
nonetheless, many have been shown to share simi-
lar characteristics for the different mGlu subtypes and
unfavorable PET imaging kinetics. Among these, 11C-
LY2428703, 11C-ITMM, and 11C-ITDM have been
shown to have a good affinity for mGlu1 in pre-
clinical studies, however, in humans, 11C-LY2428703
uptake was quite poor [48], while 11C-ITMM had
the lowest uptake in the cortex and the striatum
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[49]. 11C-ITDM has been studied in the rodent
model of HD [50] demonstrating an mGlu1 recep-
tors’ decrease in the striatum; yet these findings have
not been reiterated with PET in humans. PET imag-
ing with 18F-FIMX showed favourable kinetics and
high cerebellar distribution of mGlu1 in the human
brain; nonetheless thalamic and caudate distribution of
mGlu1 were moderate and low, respectively [51].
Hence, PET with 18F-FIMX may indeed prove useful
to assess glutamatergic neurotransmission; however
perhaps less powerful to detect striatal dysfunction in
HD.
The most studied ionotropic glutamate receptors in
relation to HD refer to N-methyl-D-aspartate (NMDA)
receptors. The function of NMDA receptors appears
to be altered in HD and related to toxic consequences
in neurons, induced by pathological excitatory gluta-
matergic neurotransmission. NMDA binding sites have
been demonstrated to decrease hugely in the insula
and the putamen among HD individuals [52] and in
that sense, NMDA PET radioligands could be useful
to assess striatal and cortical dysfunction in HD.
Several novel PET radioligands have been devel-
oped targeting NMDA receptors binding sites in
preclinical [53] as well as in studies in humans includ-
ing 11C-CNS5161 [54, 55] and 18F-GE-179 [56],
which show favorable kinetics in the human brain.
Further research with novel highly selective gluta-
matergic PET radioligands in HD may provide a better
understanding of the basal ganglia glutamatergic dys-
function and may show evidence for the development
of novel therapeutics.
PET imaging can therefore apply in assessing
alterations before and after experimental treatments
including novel neuromodulating compounds and
invasive restorative therapy.
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